STOCK TITAN

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Elevai Labs (NASDAQ: ELAB) has extended its Offer to Exchange program until November 27, 2024. The offer allows holders of Common Stock to exchange up to 15,000,000 shares for an equal number of newly issued Series B Preferred Stock. Key aspects include: the Series B Preferred Stock will be restricted and non-tradeable, potential pro-rata adjustments if oversubscribed, no capital appreciation rights, and possible dilution risks from future preferred stock issuances. The Board of Directors has not provided a recommendation regarding participation in the exchange offer.

Elevai Labs (NASDAQ: ELAB) ha esteso il suo programma di Offerta di Scambio fino al 27 novembre 2024. L'offerta consente ai detentori di Azioni Ordinarie di scambiare fino a 15.000.000 di azioni per un numero equivalente di Azioni Preferenziali di Serie B appena emesse. I punti chiave includono: le Azioni Preferenziali di Serie B saranno soggette a restrizioni e non saranno commerciabili, possibili aggiustamenti pro-rata in caso di sovrascrittura, nessun diritto di apprezzamento del capitale e potenziali rischi di diluizione derivanti da future emissioni di azioni preferenziali. Il Consiglio di Amministrazione non ha fornito raccomandazioni riguardo alla partecipazione all'offerta di scambio.

Elevai Labs (NASDAQ: ELAB) ha extendido su programa de Oferta de Intercambio hasta el 27 de noviembre de 2024. La oferta permite a los titulares de Acciones Comunes intercambiar hasta 15,000,000 de acciones por un número igual de Acciones Preferentes de Serie B recién emitidas. Los aspectos clave incluyen: las Acciones Preferentes de Serie B tendrán restricciones y no serán negociables, ajustes pro-rata potenciales si hay sobredemanda, sin derechos de apreciación de capital y posibles riesgos de dilución por emisiones futuras de acciones preferentes. La Junta Directiva no ha proporcionado una recomendación sobre la participación en la oferta de intercambio.

Elevai Labs (NASDAQ: ELAB)는 2024년 11월 27일까지 교환 제안 프로그램을 연장했습니다. 이 제안은 보통주 보유자에게 최대 15,000,000 주를 새로 발행된 B 시리즈 우선주에 대해 교환할 수 있는 기회를 제공합니다. 주요 사항에는 B 시리즈 우선주가 제한적이며 거래 불가능하고, 초과 구독 시 비례 조정 가능성, 자본 증가 권리가 없으며, 향후 우선주 발행으로 인한 희석 위험이 포함됩니다. 이사회는 교환 제안 참여에 대한 권고를 제공하지 않았습니다.

Elevai Labs (NASDAQ: ELAB) a prolongé son programme d'Offre d'Échange jusqu'au 27 novembre 2024. L'offre permet aux détenteurs d'Actions Ordinaires d'échanger jusqu'à 15 000 000 d'actions contre un nombre égal de Actions Privilégiées de Série B nouvellement émises. Les points clés incluent : les Actions Privilégiées de Série B seront soumises à des restrictions et ne seront pas négociables, des ajustements pro-rata potentiels en cas de sursouscription, aucun droit à l'appréciation du capital, et des risques potentiels de dilution à partir des futures émissions d'actions privilégiées. Le conseil d'administration n'a pas fourni de recommandation concernant la participation à l'offre d'échange.

Elevai Labs (NASDAQ: ELAB) hat sein Austauschangebot bis zum 27. November 2024 verlängert. Das Angebot erlaubt den Inhabern von Stammaktien den Austausch von bis zu 15.000.000 Aktien gegen eine gleiche Anzahl neu ausgegebener Serie B Vorzugsaktien. Wichtige Aspekte sind: die Serie B Vorzugsaktien werden eingeschränkt und nicht handelbar sein, potenzielle pro-rata Anpassungen im Falle eines Überzeichnens, keine Rechte auf Kapitalwertsteigerung und mögliche Verwässerungsrisiken aus zukünftigen Vorzugsaktienemissionen. Der Vorstand hat keine Empfehlung zur Teilnahme an dem Austauschangebot abgegeben.

Positive
  • None.
Negative
  • Series B Preferred Stock will be restricted with no active market for trading
  • Shareholders exchanging Common Stock will forfeit potential capital appreciation
  • Risk of receiving fewer shares than submitted if offer is oversubscribed
  • Potential future dilution from additional preferred stock issuances
  • Lack of Board recommendation suggests uncertainty about the offer

Insights

This stock exchange offer raises significant concerns. The company is proposing to convert up to 15 million common shares into restricted, non-tradeable Series B Preferred Stock, effectively reducing the float and limiting shareholders' liquidity options. Several red flags emerge:

  • The preferred shares will be restricted with no active market for trading
  • Shareholders will forfeit potential capital appreciation
  • Risk of dilution from future preferred stock issuance
  • No board recommendation on the offer
  • Pro-rata allocation could result in fewer shares than submitted

This unusual move suggests potential financial restructuring or capital preservation efforts. The lack of board endorsement and the restrictive terms indicate this may not be advantageous for common shareholders. The extension of the deadline could signal lower-than-expected participation.

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company’s outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company’s newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. The terms and conditions of the Offer are described in the Amended and Restated Offer to Exchange dated November 4, 2024 (“Amended and Restated Offer to Exchange”) and the related Letter of Transmittal, as they may be amended or supplemented from time to time (the Amended and Restated Offer to Exchange, together with the Letter of Transmittal, the “Offer Documents”).

The change to the Offer is that the expiration date of the Offer has been extended to one minute after 11:59 p.m. (12:00 midnight) New York City time on Wednesday November 27, 2024 unless further extended. The Offer was previously scheduled to expire at one minute after 11:59 p.m. (12:00 midnight) New York City time on November 4, 2024.

Important Overview of the Exchange Offer and Terms

The Series B Preferred Stock are Restricted and Non-Tradeable: Any Series B Preferred Stock issued in this Offer will be restricted, meaning there will be no active market for shareholders to sell the Series B Preferred Stock. The Company may extend this lock-up period as needed.

Potential Extension of the Offering: The Company may need to extend the Offer beyond the current deadline.

Adjustment of Common Stock on a Pro Rata Basis: If the total amount of Series B Preferred Stock issued exceeds the available allocation, the shares of Common Stock may be adjusted proportionally. For example, if a shareholder of Common Stock holds 100 shares, and the Series B Preferred Stock allocation is oversubscribed, such shareholder may receive fewer than 100 shares of Series B Preferred Stock as part of the Offer. Such shareholder will not receive these lost shares back if such shareholder converts the Series B Preferred Stock back into Common Stock in the future.

Termination of Offering: The Company could decide to not pursue the Offer in the best interest of the Company and its shareholders.

Absence of Capital Appreciation: Unlike Common Stock, the Series B Preferred Stock do not provide the right to benefit from any capital appreciation. Shareholders who exchange their Common Stock will forego potential gains if the stock price rises in the future.

Dilution and Future Issuance of Preferred Stock: The Company has the authority to issue additional series of preferred stock, potentially with preferential rights over the Series B Preferred Stock. This could diminish the value of both Series B Preferred Stock and Common Stock by diluting shareholder value.

No Board Recommendation: The Board of Directors has not provided a recommendation regarding participation in the Offer. This lack of endorsement may indicate potential uncertainties or a reluctance to promote the Offer directly to shareholders​.

This press release is for informational purposes only and shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy the Series B Preferred Stock or any other securities. Any offers of the Series B Preferred Stock will be made only by means of the Amended and Restated Offer to Exchange. 

The complete terms and conditions of the Offer are set forth in the Amended and Restated Offer to Exchange that has been filed with the U.S. Securities and Exchange Commission (“SEC”) on Schedule TO. Stockholders of Elevai are strongly encouraged to read the Schedule TO and related exhibits because they contain important information about the Offer. The Schedule TO and related exhibits will be available without charge on the SEC’s website at http://www.sec.gov and will be delivered without charge to all stockholders of Elevai.

About Elevai Labs, Inc.

Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in Elevai’s filings with the SEC, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:

IR@ElevaiLabs.com


FAQ

When does Elevai Labs' (ELAB) stock exchange offer expire?

The offer expires at 12:00 midnight New York City time on November 27, 2024, unless further extended.

How many shares of Common Stock can be exchanged in Elevai Labs' (ELAB) offer?

Up to 15,000,000 shares of Common Stock can be exchanged for an equal number of Series B Preferred Stock.

What is the exchange ratio for Elevai Labs' (ELAB) stock exchange offer?

The exchange ratio is one-to-one: each share of Common Stock can be exchanged for one share of Series B Preferred Stock.

Can Elevai Labs' (ELAB) Series B Preferred Stock be traded after the exchange?

No, the Series B Preferred Stock will be restricted and non-tradeable, with no active market for shareholders to sell.

Elevai Labs, Inc.

NASDAQ:ELAB

ELAB Rankings

ELAB Latest News

ELAB Stock Data

997.25k
501.53M
72.98%
18.2%
19.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH